Novel therapeutic strategies targeting ASK1 in NASH
S Schuster, AE Feldstein - Nature Reviews Gastroenterology & …, 2017 - nature.com
S Schuster, AE Feldstein
Nature Reviews Gastroenterology & Hepatology, 2017•nature.comCurrently, no pharmacological therapies are approved for the treatment of NASH. A new
study now identifies CASP8 and FADD-like apoptosis regulator (CFLAR) as a novel
suppressor of NASH and its associated disorders in a process dependent on the activation
of apoptosis signal-regulating kinase 1 (ASK1).
study now identifies CASP8 and FADD-like apoptosis regulator (CFLAR) as a novel
suppressor of NASH and its associated disorders in a process dependent on the activation
of apoptosis signal-regulating kinase 1 (ASK1).
Currently, no pharmacological therapies are approved for the treatment of NASH. A new study now identifies CASP8 and FADD-like apoptosis regulator (CFLAR) as a novel suppressor of NASH and its associated disorders in a process dependent on the activation of apoptosis signal-regulating kinase 1 (ASK1).
nature.com